



ImVision Therapeutics enters strategic partnership with IDT Biologika

Muttenz, Switzerland – 16 December 2010- ImVision Therapeutics AG, a biopharmaceutical company pioneering intralymphatic immunotherapy (ILIT™), today announced that it has entered a strategic partnership with IDT Biologika, a globally-integrated contract manufacturer of vaccines and biopharmaceuticals.

Under the terms of the deal, IDT Biologika will take responsibility for all activities relating to manufacturing ImVision's product candidates. This includes the development of GMP manufacturing processes, production of GMP batches for clinical development, upscale and commercialization of manufacturing processes and manufacturing products for commercial sale. In addition, ImVision will be able to tap into IDT's existing competences and capabilities relating to pharmaceutical product development (i.e. regulatory affairs, quality control and supply chain management). IDT Biologika also plans to make an equity investment in ImVision.

"We recently obtained further validation of our technology platform through the successful completion of our first human clinical study with CAT-MAT (IVN201). These results and especially our new strategic partnership with IDT Biologika, which gives us access to world class expertise in industrialisation of biopharmaceutical products as well as state-of-the art production capacities, have ensured that we are more than well positioned to continue the clinical development of our lead product. We also plan to extend our product pipeline and bring our additional product candidates, Birch-MAT and Mite-MAT, with the support of IDT Biologika into clinical testing within the next two to three years," commented Martin Steiner, ImVision's CEO.

Ralf Pfirmann, CEO of IDT Biologika added: "We believe that ImVision can dramatically change the way of allergy treatment with its intralymphatic immunotherapy (ILIT). With only three injections and a very favourable safety profile, ILIT has a strong competitive advantage. With the backing of our knowledge in developing efficient and compliant production processes and creating successful marketing strategies ImVision will be able to enter the market straight forward. We are also evaluating the upside potential of ImVision's technology for our own portfolio."

ImVision is also currently conducting a Series B financing which is intended to fund the completion of a Phase II clinical study with the Company's lead product, CAT-MAT as well as the advancement into clinical development of its Birch-MAT and Mite-MAT product candidates.

About ImVision Therapeutics

ImVision Therapeutics is a private biotechnology company headquartered in Switzerland. The Company is the pioneer in intralymphatic immunotherapy (ILIT™), a proprietary technology for the delivery of immunotherapy in the treatment of allergies. ILIT is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By combining ILIT with another proprietary technology, Modular Antigen Transporter (MAT), ImVision leverages the potential of ILIT for the

development of drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergy. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in future.

www.imvision-therapeutics.com

About IDT Biologika

IDT Biologika GmbH is an innovative, privately-held company with nearly 90 years of experience in researching, developing, manufacturing, and marketing of biologics. The company focuses on three core areas – animal health, human vaccines, and pharmaceuticals: For **veterinary markets**, IDT Biologika manufactures and markets a comprehensive range of high-quality vaccines and other products for animal health. For **vaccines**, IDT Biologika offers development services and manufacturing facilities for clinical phase I to III as well as commercial supplies for leading edge viral and bacterial human vaccines, addressing health issues such as tuberculosis, AIDS, malaria and pox. For **pharmaceutical markets**, IDT Biologika specializes in the development and manufacture of sterile liquid drugs, providing fully-integrated services range from formulation development and clinical manufacturing through large-scale production, packaging and quality control. The company has experience in technically sophisticated projects, such as innovative biopharmaceuticals and lyophilized compounds, in EMA- and FDA-inspected facilities, most of which have been built within the last five years. IDT Biologika is a member of the Klocke Group. With more than 1300 employees at six locations worldwide the Klocke Group has been offering its customers a complete range of services for contract manufacture and contract packaging, from development, production and filling through to the development of customized packaging methods and packing for more than 40 years. The Group also has extensive experience in contract manufacturing of solid dosage forms and cytostatics.

www.idt-biologika.com.

Contact:	
Dr. Martin Steiner CEO ImVisioN Therapeutics Tel: + 49 (0) 511 53 88 96 76 info@imvision-therapeutics.com	Dr. Robert Mayer Senior Account Manager College Hill Tel : +49 (0) 89 5700 1806 robert.mayer@collegehill.com